LJPC - La Jolla Pharmaceutical Company

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
17,752
10,056
0
616
1,057
Cost of Revenue
2,507
1,643
-
-
0
Gross Profit
15,245
8,413
-
-
1,057
Operating Expenses
Research Development
101,293
117,302
84,575
62,288
29,092
Selling General and Administrative
63,625
85,162
30,852
16,700
13,934
Total Operating Expenses
164,918
202,464
115,427
78,988
43,026
Operating Income or Loss
-149,673
-194,051
-115,427
-78,372
-41,969
Interest Expense
11,184
7,303
-
-
-
Total Other Income/Expenses Net
-
-
624
187
57
Income Before Tax
-158,264
-199,469
-114,803
-78,185
-41,912
Income Tax Expense
-
-
-
-
-
Income from Continuing Operations
-158,264
-199,469
-114,803
-78,185
-41,912
Net Income
-158,264
-199,469
-114,803
-78,185
-41,912
Net Income available to common shareholders
-158,264
-199,469
-114,803
-78,185
-41,912
Reported EPS
Basic
-
-7.85
-5.41
-4.54
-2.68
Diluted
-
-7.85
-5.41
-4.54
-2.68
Weighted average shares outstanding
Basic
-
25,422
21,215
17,228
15,651
Diluted
-
25,422
21,215
17,228
15,651
EBITDA
-
-192,166
-114,159
-78,372
-41,969